Amboy Street invests in leading virtual abortion provider, Hey Jane

Amboy Street Ventures participates in Hey Jane’s $6.1M round.

Hey Jane, the leading telemedicine abortion clinic, is the latest startup to join the Amboy Street Ventures portfolio of top women’s health and sexual health companies. We are excited to participate in Hey Jane’s $6.1M raise alongside other female founded VC funds including Ulu Ventures, The Helm, Portfolia, and G9. The raise was covered by Fortune and Bloomberg with comments from our Founding Partner, Carli Sapir.

Hey Jane prescribes abortion medication to patients online, delivers the medication to the home, and provides follow-up care and community. Since its inception in 2021, Hey Jane has quickly scaled to serve 15,000 patients and plans to expand into other stigmatized areas of women’s health, starting with post-partum depression. When so many companies shy away from these areas for fear of repercussions, Hey Jane is tackling them head-on by providing necessary, accessible, convenient, and safe solutions for women, and in doing so, has created an extremely loyal customer base.

As we point out in our blog post about the abortion access space, VC funds historically have stayed away from this vertical because of the Vice Clause and fear of losing Limited Partners (read here). This oversubscribed $6.1M round is a turning point, demonstrating that VCs are starting to invest in and fuel abortion access innovation – and we are thrilled to be a part of this shift.

Hey Jane’s US-based board-certified medical providers prescribe medication abortion in California, Colorado, Connecticut, Illinois, New Jersey, New Mexico, New York, and Washington. The next wave of advancements for the company includes scaling accessibility through geographic expansion and partnerships, increasing affordability through insurance coverage, and escalating impact through new product offerings in other underserved areas of women’s health.

“We’re more motivated than ever to continue innovating and serving as a category leader at such a pivotal moment in history. Despite the barriers that this category can face when seeking investment, Hey Jane has touted rapid growth while continuing to provide safe and private abortion care to thousands since our initial launch in 2021,” says Kiki Freedman, co-founder and CEO.

Amboy Street is committed to investing in companies that empower women to take charge of their health, and democratizing abortion access is essential to this mission. We are proud supporters of Hey Jane.

For more information, visit https://www.heyjane.co/ and mentions in NY Times, Forbes, and TechCrunch.

Continue Reading

Amboy Street Invests in Alloy’s $16M Series A

Amboy Street Ventures is excited to announce its latest investment in Alloy Women’s Health, a digital health company committed to providing women the care they need through menopause and beyond.

Top 10 Deals of 2024: BillionToOne Becomes a Unicorn

In this blog, we unpack prenatal genetic screening company, BillionToOne's $130 million Series D raise to showcase the increasing number of women’s health companies reaching unicorn status. We are seeing women’s health companies close considerable growth rounds while early-stage funding remains robust.

Top 10 Deals of 2024: Urinary Incontinence MedTech $3.7B Acquisition

This week we explore a major acquisition in a segment of women’s health that is often stigmatized yet universally experienced by women at some point in their lifetime: urinary incontinence.

Amboy Street Invests in Alloy’s $16M Series A

Amboy Street Ventures is excited to announce its latest investment in Alloy Women’s Health, a digital health company committed to providing women the care they need through menopause and beyond.

Top 10 Deals of 2024: BillionToOne Becomes a Unicorn

In this blog, we unpack prenatal genetic screening company, BillionToOne's $130 million Series D raise to showcase the increasing number of women’s health companies reaching unicorn status. We are seeing women’s health companies close considerable growth rounds while early-stage funding remains robust.

Fast track our industry.
Get in touch today.